Ionis Pharmaceuticals Inc. [NASDAQ: IONS] plunged by -$2.06 during the normal trading session on Thursday and reaching a high of $58.23 during the day while it closed the day at $56.51. Ionis Pharmaceuticals Inc. stock has also gained 1.16% of its value over the past 7 days. However, IONS stock has inclined by 27.48% in the 3 months of the year. Over the past six months meanwhile, it has lost -10.17% and lost -6.46% year-on date.
The market cap for IONS stock reached $7.64 billion, with 139.43 million shares outstanding and 132.36 million shares in the current float. Compared to the average trading volume of 933.19K shares, IONS reached a trading volume of 1150578 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Get 12 free stock market lessons delivered to your email from Investor's Business Daily, the leader in investing education for over 35 years. We’ll cover the basics of better investing and show you how to give yourself an edge in the market.
GET FREE LESSON outside the norm.
Here’s what leading stock market gurus have to say about Ionis Pharmaceuticals Inc. [IONS]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for IONS shares is $67.94 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on IONS stock is a recommendation set at 2.60. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Oppenheimer have made an estimate for Ionis Pharmaceuticals Inc. shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on June 01, 2020. While these analysts kept the previous recommendation, RBC Capital Mkts raised their target price to Outperform. The new note on the price target was released on May 13, 2020, representing the official price target for Ionis Pharmaceuticals Inc. stock. Previously, the target price had yet another raise to $73, while Citigroup analysts kept a Buy rating on IONS stock.
The Average True Range (ATR) for Ionis Pharmaceuticals Inc. is set at 1.93, with the Price to Sales ratio for IONS stock in the period of the last 12 months amounting to 7.97. The Price to Book ratio for the last quarter was 5.79, with the Price to Cash per share for the same quarter was set at 17.63. Price to Free Cash Flow for IONS in the course of the last twelve months was 39.47 with Quick ratio for the last quarter at 9.80.
IONS stock trade performance evaluation
Ionis Pharmaceuticals Inc. [IONS] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 1.16. With this latest performance, IONS shares gained by 1.09% in over the last four-week period, additionally sinking by -10.17% over the last 6 months – not to mention a drop of -12.31% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for IONS stock in for the last two-week period is set at 51.94, with the RSI for the last a single of trading hit 48.65, and the three-weeks RSI is set at 52.21 for Ionis Pharmaceuticals Inc. [IONS]. The present Moving Average for the last 50 days of trading for this stock 54.83, while it was recorded at 57.99 for the last single week of trading, and 57.59 for the last 200 days.
Ionis Pharmaceuticals Inc. [IONS]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Ionis Pharmaceuticals Inc. [IONS] shares currently have an operating margin of +32.59 and a Gross Margin at +98.18. Ionis Pharmaceuticals Inc.’s Net Margin is presently recorded at +26.42.
Return on Total Capital for IONS is now 16.99, given the latest momentum, and Return on Invested Capital for the company is 15.06. Return on Equity for this stock inclined to 23.54, with Return on Assets sitting at 10.05. When it comes to the capital structure of this company, Ionis Pharmaceuticals Inc. [IONS] has a Total Debt to Total Equity ratio set at 53.53. Additionally, IONS Total Debt to Total Capital is recorded at 34.87, with Total Debt to Total Assets ending up at 24.36. Long-Term Debt to Equity for the company is recorded at 53.40, with the Long-Term Debt to Total Capital now at 34.78.
Reflecting on the efficiency of the workforce at the company, Ionis Pharmaceuticals Inc. [IONS] managed to generate an average of $362,990 per employee. Receivables Turnover for the company is 29.62 with a Total Asset Turnover recorded at a value of 0.38.Ionis Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 9.80 and a Current Ratio set at 9.90.
Earnings per share (EPS) analysis for Ionis Pharmaceuticals Inc. [IONS] stock
With the latest financial reports released by the company, Ionis Pharmaceuticals Inc. posted -0.01/share EPS, while the average EPS was predicted by analysts to be reported at -0.27/share.When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 96.30%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for IONS. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Ionis Pharmaceuticals Inc. go to 49.00%.
Ionis Pharmaceuticals Inc. [IONS]: Insider Ownership positions
There are presently around $6,936 million, or 87.00% of IONS stock, in the hands of institutional investors. The top three institutional holders of IONS stocks are: FMR LLC with ownership of 20,960,227, which is approximately 0% of the company’s market cap and around 0.20% of the total institutional ownership; VANGUARD GROUP INC, holding 12,053,561 shares of the stock with an approximate value of $705.98 million in IONS stocks shares; and BAILLIE GIFFORD & CO, currently with $512.24 million in IONS stock with ownership of nearly -0.504% of the company’s market capitalization.
Positions in Ionis Pharmaceuticals Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 144 institutional holders increased their position in Ionis Pharmaceuticals Inc. [NASDAQ:IONS] by around 6,294,390 shares. Additionally, 205 investors decreased positions by around 8,723,824 shares, while 76 investors held positions by with 103,401,164 shares. The mentioned changes placed institutional holdings at 118,419,378 shares, according to the latest SEC report filing. IONS stock had 35 new institutional investments in for a total of 838,505 shares, while 64 institutional investors sold positions of 1,273,573 shares during the same period.